Latest news

Latest News

The Patient Advisory Board takes a great leap forward in raising awareness about RSV

A key aspect to prevent the infection caused by RSV (Respiratory Syncytial Virus) and its sequels amongst young babies is making parents more aware of its existence. This last year, RESCEU’s Patient Advisory Board (PAB) has made a great leap forward by designing and implementing a plan aimed at promoting awareness about this common and …

ISAG encourages RESCEU to export its framework to fight vaccine preventable diseases such as COVID-19

The International Scientific Advisory Group (ISAGs) played a primary role, at RESCEU 4th GAM. Precisely, one of the main responsibilities of this body of experts on scientific and technical matters relevant to the project is to provide advice to the General Assembly and the Steering Committee and support their decision making. In this year’s General Assembly …

Early career researchers take the floor at RESCEU’s virtual 4th GAM

RSV research has a bright future judging by the good work and implication shown by the early career researchers during RESCEU’s virtual 4th General Assembly Meeting (GAM). Indeed, this year’s edition wanted to bring into focus the contribution young scientists are making to the project which intends to build knowledge on RSV for the future development …

RESCEU’s GAM goes virtual to continue fostering scientific debate around RSV

RESCEU celebrated its 4th General Assembly Meeting last 17th and 18th of June in exceptional circumstances due to COVID-19.   The plans to congregate RESCEU’s Consortium members in the historical city of Edinburg to celebrate the 4th General Assembly Meeting (GAM) in a three-day event were cut short by COVID-19. Given this year’s challenging circumstances, knowledge sharing, and scientific …

Get to Know the RESCEU Team! This month we talk to Joanne Wildenbeest from UMCU

  Joanne Wildenbeest is a paediatric infectious diseases specialist at the Wilhelmina Children’s Hospital, University Medical Center Utrecht. Tell us about your professional career. I am a paediatric infectious diseases specialist and researcher at the Wilhelmina Children’s Hospital, University Medical Center Utrecht. I studied medicine at Ghent University in Belgium. After graduating I started my …

RESCEU Mid-Term Review

In February, IMI organised the Mid-Term Review of our project that took place in Brussels. A team of 20 people represented our consortium in front of our Project Officer, Isabella Tamagnini, and three reviewers: Dimitrios Athanasious, Dirk Jochmans and Tanel Tenson. During the meeting, a representative of each work package exposed their achievements and explained …

Get to Know the RESCEU Team! This month we talk to Nicolas Voirin  from SP

    Nicolas Voirin is founder and managing member of EPIMOD, a company providing applied research services in epidemiology and modeling of infectious diseases. As a scientist, his main interest is understanding infectious diseases epidemiology, prevention, treatment and control through statistical and mathematical modelling. Tell us about your professional career. I received training in biology, …

Prevention of Severe RSV in Infants: ongoing studies and vaccine strategies

Harish Nair, University of Edinburgh (UK), RESCEU Project Coordinator, and Louis J. Bont, University Medical Center Utrecht (NL), RESCEU Work Package Leader, have recently taken part in an Experts Panel Discussion on RSV, hosted by the platform Peervoice and endorsed by ReSViNET. Together with Asuncion Mejias, from the Nationwide Children’s Hospital, Columbus, Ohio (USA), they …

RESCEU presented at the EMA Vaccine Working Party Meeting

RESCEU Work Package 2 representatives met with the EMA Vaccine Working Party (VWP) on June 7th at the EMA in London, as part of the RESCEU efforts for establishing continuous communication and collaboration with Regulatory Bodies. The meeting began with a presentation of RESCEU, including an overview of the project and a detailed explanation of …

EMA ITF Briefing Meeting with RESCEU representatives held in London

An EMA ITF Briefing Meeting with RESCEU representatives took place on March 16th at the EMA headquarters, as part of the RESCEU efforts for establishing continuous communication and collaboration with Regulatory Bodies. The purpose of this collaboration is to allow RESCEU to receive fundamental regulatory input but also provide, thanks to its experts and the data …

First RESCEU’s Clinical Studies patients tested

RESCEU’s clinical studies have started, with the aim of gathering data and addressing knowledge gaps on the impact of RSV infections. The investigation is building on the knowledge of a varied team of partners from universities and public health institutions, and includes 3 cohort studies on vulnerable populations (infants, older adults, COPD subjects) and one …

RESCEU becomes ISARIC member

We are glad to announce the RESCEU membership in the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). It is a global initiative aiming to ensure that clinical researchers have the open access protocols and data-sharing processes needed to facilitate a rapid response to emerging diseases that may turn into epidemics or pandemics. Please follow …

Kick off meeting

After many months of intensive preparatory work following a competitive call process, the Respiratory Syncytial Virus Consortium in Europe (RESCEU) was launched in January 2017. The RESCEU project aims to develop robust evidence on RSV disease burden and economic impact; create a sustainable Europe-wide multidisciplinary, multi-stakeholder community from academia, public health, scientific societies, patient organisations, …

€29m research grant to assess risk posed by deadly lung infections

Experts have received €29 million (£24m) to investigate serious lung infections that particularly affect babies and older people. Diseases caused by respiratory syncytial virus (RSV) are estimated to affect more than 30 million children under five each year throughout the world. The virus also affects older people and those with weakened immune systems, including cancer …